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EDITORIAL REVIEW
The metabolism and mechanism of action of
1 ,25-dihydroxyvitamin D3
In this review, I will summarize recent information concern-
ing the metabolism and mechanism of action of 1 ,25-dihydroxy-
vitamin D3. New concepts concerning the formation and trans-
port of precursors will also be briefly presented.
Sources of Vitamin D'
Formation of vitamin D3 in the skin
Vitamin D3 is not a vitamin (an essential exogenous
micronutrient) in a strict sense because it is formed endoge-
nously in the skin from a precursor, 7-dehydrocholesterol [1].
Diminished sunlight exposure that has accompanied our way of
life has necessitated the ingestion of the vitamin via the diet.
Early work clearly established that 7-dehydrocholesterol is
converted to previtamin D3, in vitro as well as in vivo, in the
presence of ultraviolet light [2—6]. Thermal isomerization of the
previtamin results in the formation of the vitamin. Recently,
attention has focused on the formation of vitamin D3 in the skin
of man and experimental animals, the effect of the duration of
sunlight exposure, the effect of pigmentation and the role of
vitamin D binding protein on the transport of the vitamin out of
the skin [7—10]. The amount of previtamin D3 formed is depen-
dent upon the duration of sunlight exposure, the spectral
properties of the incident light (light of 295 5 nm being most
efficient in the photolytic cleavage of the B-ring), and the
amount of pigmentation present in skin. In blacks, the amount
of vitamin D3 formed after exposure to a given amount of
ultraviolet light is considerably less than that in Caucasions [9].
However, if the duration and intensity of exposure is increased,
then there is equivalent, or nearly equivalent, formation of
vitamin D3 in the skin of blacks when compared to Caucasians.
Holick and co-workers have hypothesized that vitamin D
binding protein may help in the transport of vitamin D3 from
skin into plasma [81. Vitamin D binding protein, a 52,000 to
58,000 molecular weight protein, binds poorly to previtamin D3
but binds with a greater affinity to vitamin D3. It has been
suggested that vitamin D binding protein transports vitamin D3
out of the skin into the systemic circulation and thus maintains
relatively low concentrations of vitamin D3 within skin; this
allows the thermal isomerization of previtamin D3 to vitamin D3
to proceed at a more rapid rate by decreasing the concentra-
tions of vitamin D3 within the skin [8]. Whether this process is
of physiological importance in vivo is not known.
Absorption of vitamin D from the diet
Vitamin D3 (or vitamin D2), present in food, is absorbed via
the intestinal lymphatics [11]. Here the vitamin resides in the
chylomicron fraction. About 50% of the vitamin in chylomi-
crons is transferred to vitamin D binding globulin in blood
before uptake by the liver [12]. Because not all radiolabeled
vitamin D3 is transferred to vitamin D binding protein, other
proteins such as albumin may play a role in the transport of
vitamin D3 [13, 14].
The formation of 25-hydroxyvitamin D3 in the liver
Vitamin D3, is converted to an intermediary metabolite,
25-hydroxyvitamin D3, in the liver [15, 16]. The enzyme that
catalyzes this reaction is present both in liver microsomes as
well as in liver mitochondria [17, 18]. The microsomal enzyme
requires NADPH and a soluble cytosolic factor for its activity.
It is a cytochrome P-450-like enzyme that has recently been
characterized by Yoon and DeLuca [19]. The microsomal
enzyme has a lower Michaelis constant (Km) and is better
regulated than the mitochondrial enzyme, which has a higher
Michaelis constant (Km) and is poorly regulated [17, 18]. The
administration of large doses of vitamin D3 results in the
progressive increase in circulating levels of 25-hydroxyvitamin
D3, as the process of 25-hydroxylation is poorly regulated, and
at higher concentrations of vitamin D3 the mitochondrial en-
zyme will form significant quantities of 25-hydroxyvitamin D3.
It is for this reason that the circulating level of 25-hydroxyvi-
tamin D is a good index of vitamin D3 reserves. The adminis-
tration of 1,25-dihydroxyvitamin D3 has been shown to de-
crease the concentration of 25-hydroxyvitamin D3 in plasma in
vivo [20]. The physiologic significance of this is not clear, as we
have shown that phosphate deprivation (a maneuver that in-
creases 25-hydroxyvitamin D3 la-hydroxylase activity and
1,25-dihydroxyvitamin D concentrations in plasma) does not
suppress 25-hydroxyvitamin D3 levels [21]. Conversely, phos-
phate ingestion (which decreases 1 ,25-dihydroxyvitamin D con-
centrations in plasma) does not alter 25-hydroxyvitanün D
concentrations in blood [22].
Vitamin D binding globulin
'The term vitamin D refers to both vitamin D3 (9,10-secocholesta-
5,7, 10(l9)-triene-313-ol) and vitamin D2 (9, l0-secocholesta-5,7,10(19)22-
tetraene-3/3-ol) (5Z isomers). While vitamin D3 is formed endogenously,
vitamin D2 is not.
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Vitamin D binding globulin is a protein that has a molecular
weight of approximately 52,000 daltons in the rat and about
58,000 daltons in the human [23]. It binds 25-hydroxyvitamin D3
with high affinity and binds other vitamin D metabolites, such as
vitamin D3 and 1 ,25-dihydroxyvitamin D3, with lower affinity.
24,25-Dihydroxyvitamin D3 and 25,26-dihydroxyvitamin D3,
which have both 3/3-hydroxy and 25-hydroxy groups, bind to
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vitamin D binding protein with an affinity equal to that of
25-hydroxyvitamin D3. The distance between the 3/3-hydroxy
group and another hydroxyl group on the molecule is of
importance as ics-hydroxyvitamin D3 (C-i and C-3 hydroxyl
groups in close proximity) binds poorly to vitamin D binding
protein whereas Ii a-hydroxyvitamin D3 which has 3/3 and I la
hydroxy groups (intermediate distance between C-3 and C-25)
binds with intermediate affinity [24]. Sequencing of a comple-
mentary DNA clone for vitamin D binding protein has shown
that there is some homology between vitamin D binding protein
and serum albumin and alpha-feto protein [25, 261. The physi-
ological role of this protein is uncertain. It may act as a
25-hydroxyvitamin D "buffer", and some have thought that it
may help in the internalization of vitamin D sterols. The protein
binds tightly to actin [26, 27]. Some investigators believe that
the amounts of vitamin D binding protein influence the concen-
trations of "free i,25-dihydroxyvitamin D" in plasma and that
the concentrations of "free hormone" are important in deter-
mining the biologic activity of the hormone in any given
condition [14, 28, 29].
The formation of 1,25-dihydroxyvitamin B3
1,25-Dihydroxyvitamin D3, the hormonal form of the vitamin,
is formed in the mitochondria of the proximal tubules of the
nephron [30—38]. The enzyme is a cytochrome P-450-like,
mixed function oxidase that utilizes molecular oxygen as the
source of oxygen [39—431. The characteristics of this enzyme in
the chicken have been well delineated, and a summary of the
characteristics of this enzyme complex is shown in Figure 1.
Warner and also Crivello suggest that in the rat and cow, the
enzyme is not of the same nature as in the chicken [44, 451.
Others, however, have shown that product isolated by the
former workers is not I ,25-dihydroxyvitamin D3, and that the
rat enzyme is similar to the chicken enzyme [46]. There are
several factors that regulate the activity of the 25-hydroxyvita-
mm D3 lia-hydroxylase enzyme [47, 48]. Many of them are
Fig. 1. The nature of the 25-hydroxyvitamin
D3-la-hydroxylase enzyme (Taken from
DeLuca HF, reference 1, with permission of
the publisher).
functional only in certain species and under certain sets of
experimental conditions. The major factors regulating the ac-
tivity of the 25-hydroxyvitamin D3 I ts-hydroxylase are parathy-
roid hormone, the concentration of serum phosphorus, 1,25-
dihydroxyvitamin D3 itself, and serum calcium directly. A
summary of the factors that are known to alter 1 a-hydroxylase
enzyme activity is given in Table 1 (taken from reference 47;
detailed references about substances or factors altering 1,25-
dihydroxyvitamin D3 concentrations or 25-hydroxyvitamin D3
lix-hydroxylase activity are given in this reference).
The catabolism of 1,25-dihydroxyvitamin B3
I ,25-Dihydroxyvitamin D3 is metabolized by several pro-
cesses in experimental animals as well as man [47, 49—53]. The
precise delineation of these processes and their regulation is of
importance, as circulating levels of a hormone depend not only
upon its rate of formation but also upon its rate of degradation.
The metabolic pathways involved in the degradation of 1,25-
dihydroxyvitamin D3 are as follows: 1) side chain oxidation to
an inactive product, calcitroic acid [54—571; 2) 24-hydroxylation
to I ,24,25-trihydroxyvitamin D3 in several tissues including the
kidney, the intestine, cartilage, and perhaps other tissues as
well [58—641; 3) formation of 24-oxo- 1 ,25-dihydroxyvitamin D3
[65, 66]; 4) formation of 1,25-dihydroxyvitamin D3 23,26-
lactone [67]; 5) biliary excretion as polar metabolites such as
1,25-dihydroxyvitamin D3 monoglucuronides in bile 147, 52, 68,
69]. The products that are excreted in bile are in the form of
glucuronides and other polar charged materials that may be
sulfates of I ,25-dihydroxyvitamin D3. There are neutral polar
steroids present in bile that could be glycosides of 1,25-
dihydroxyvitamin D3. The products of 1 ,25-dihydroxyvitamin
D3 undergo an enterohepatic recirculation that may be per-
turbed in certain pathologic states [70]. Model glucuronides and
glucosides of vitamin D3 analogs are biologically active follow-
ing hydrolysis to the free sterols and thus, the aglycones of
conjugates of vitamin D analogs may be liberated in the
Succinate f
Isocitrate-
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Table 1. Factors altering serum 1,25-dihydroxyvitamin D3
concentrations or 25-hydroxyvitamin D3 la-hydroxylase activitya
Factor
Level or
activity
change of
substance
Effect on 1 ,25(OH)2D3
Levels or 1 ,25(OH)2D3
la-hydroxylase activity
Animals Humans
Parathyroid hormone Increase
Decrease
+ +
— —
Serum inorganic phosphorus Increase
Decrease
— —
+ +
1 ,25-Dihydroxyvitamin D3 Increase
Decrease
— ?
+
Calcium (direct) Increase
Decrease
?
+ +
Calcitonin Increase
Decrease
+ , — ,0 +
?
Hydrogen ion Increase
Decrease
— 0
?
Sex steroids Increase
Decrease
+ +
?
Prolactin Increase
Decrease
+ 0
?
Growth hormone Increase
Decrease
+ 0,—, +
?
Glucocorticoids Increase
Decrease
—
— ,0, +
?
Thyroid hormone Increase
Decrease — + b
Pregnancy + +
a from Kumar, reference 47, with permission of the publisher. Minor
modifications have been made.
Symbols are: +, Stimulation or increase; —, suppression or de-
crease; 0, no effect; ?, effect not known.
' Effects may be secondary to changes in calcium, phosphorus, or
parathyroid hormone.
intestine following hydrolysis in that organ [71—73]. 6) Forma-
tion of 1 ,25,26-trihydroxyvitamin D3 [74 75].
In experimental animals, side chain oxidation and biliary
excretion account for about 50% of the excretion of 1,25-
dihydroxyvitamin D3. The physiological role of the enterohe-
patic circulation has not been precisely quantitated. There are
conflicting views about whether this is important in the
enterohepatic physiology of 25-hydroxyvitamin D3—a metabo-
lite of vitamin D3 with a much longer half—life than 1,25-
dihydroxyvitamin D3 [76]. The exact pathophysiologic role of
the enterohepatic physiology of 1 ,25-dihydroxyvitamin D3 in
various disease states requires further examination.
Production and degradation rates of dihydroxylated vitamin
D metabolites in man
1 ,25-Dihydroxyvitamin D3 is rapidly cleared from the circu-
lation of man [5 1—53]. Following a dose of intravenous 1,25-
dihydroxyvitamin D3 of high specific activity, <50% of the
administered dose is present in plasma within a period of five
minutes. A slower component of elimination has a half—life of
approximately 10 hours. This corresponds well with the bio-
logic half—life of 1 ,25-dihydroxyvitamin D3 in man. The meta-
bolic production rate and clearance rate of 1,25-dihydroxyvi-
tamin D3 are shown in Table 2 and are compared with the
metabolic production rate of another dihydroxylated vitamin D
metabolite, 24,25-dihydroxyvitamin D3 [51, 53, 77]. The dispo-
sition of radioactivity in plasma, stool, and urine, following the
administration of these substances in man, is also shown in
Table 2. Bolus and continuous infusion techniques have been
used to determine the metabolic clearance rate and production
rate of 1 ,25-dihydroxyvitamin D3, In general, they have yielded
similar results [78]. 1 ,25-Dihydroxyvitamin D3 concentrations
in plasma decrease with age in humans, and we have shown that
this is due, at least in part, to a decrease in the responsiveness
of the 25-hydroxyvitamin D3 1 a-hydroxylase enzyme to para-
thyroid hormone in direct proportion to the decrease of glomer-
ular filtration with age (Table 3) [79].
A majority (—60 to 70%) of administered radioactive 1,25-
dihydroxyvitamin D3 is eliminated in stool as more polar
metabolites. Thus, the biliary excretion and fecal route of
excretion plays a major role in the elimination of 1,25-
dihydroxyvitamin D3 in man.
In conclusion, 1 ,25-dihydroxyvitamin D3 is catabolized by a
variety of metabolic processes which rapidly remove it from the
organism. These processes are either induced by 1,25-dihy-
droxyvitamin D3 itself or are not regulated by dietary calcium
and phosphorus intakes [47].
The mechanism of action of 1,25-dihydroxyvitamin D3
The major effects of vitamin D3 (via 1 ,25-dihydroxyvitaniin
D3) are to increase the active absorption of calcium from the
proximal intestine and to bring about the mineralization of bone
[1]. In the following section, the mechanism of action of
1,25-dihydroxyvitamin D3 in the intestine is reviewed. The
intestine is a tissue in which the vitamin has its most marked
effects. It has the added advantage in that biochemical events in
the enterocyte can be associated with a physiological effect,
namely the transport of calcium across the mucosa.
The mechanism of action of 1,25-dihydroxyvitamin D3 in the
intestine
The absorption of calcium from the intestinal lumen has both
active and passive components [80]. The former (active) trans-
port process is enhanced by 1 ,25-dihydroxyvitamin D3. As
shown in Figure 2, from a thermodynamic standpoint, the
movement of calcium into the cell from intestinal lumen is with
an electrical and a concentration gradient. On the contrary, the
concentration of calcium within the cell is considerably lower
than that in the extracellular fluid, and therefore, the movement
of calcium out of the cell into the extracellular fluid is against a
concentration gradient. The extrusion of calcium into extracel-
lular fluid is also against an electrical gradient. Consequently,
energy needs to be expended in order to move this ion out of the
cell and into extracellular fluid. It is important to bear in mind
that other mechanisms such as diffusion through tight junctions
could exist, at least in theory, for calcium movement across the
epithelial cell layer. Transcellular movement is, however, the
major pathway for calcium transport across the duodenal
mucosa [81].
Other considerations with respect to the movement of cal-
cium across the intestinal cell layer include the fact that sodium
is necessary for the transport of calcium across this epithelial
cell, and in the absence of sodium, the active transport of
calcium is greatly depressed [82]. A majority of investigators
are of the view that under controlled conditions, the movement
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Table 2. Metabolic clearance, production and excretion rates of I ,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in normal mana
a Taken from references 5 1—53,77
b Both I ,25(OH)2D3 and 24,25(OH),D3 or products thereof undergo an enterohepatic circulation in man
Table 3. GFR and serum values in different groups of normal women
of various ages studied before and after the infusion of bovine (1 = 34)
parathyroid hormonea
GFR mi/mm per 1.73 m2
Serum values
Calcium mg/di
Phosphorus mg/dl
Basal
IncrementaV'
Alkaline phosphatase U/liter
iPTH jdEq/ml
25(OH)D ng/ml
I ,25(OH)2D pg/mI
Basal
Incremental5
Urine cAMP nM/100 ml
GFR
A B C
a from Tsai et al, reference 79, with permission of the publisher
b Difference between levels at beginning and end of bPTH(l-34)
infusion. Results are shown as mean SE. Group A, age, 37 4 years
(mean SD); B, age, 61 -- 6 years; C, age, 78 4 years. Correlation
coefficients for linear regression of variables GFR vs. age; P < 0.001;
basal 1 ,25-dihydroxyvitamin D3 vs. age, NS; incremental 1 ,25-dihy-
droxyvitamin D3 vs. age, P < 0.01; incremental 1 ,25-dihydroxyvitamin
D3 vs. GFR, P < 0.001
of calcium across the intestinal cell layer is dependent upon
protein synthesis [83, 84]. Some investigators, however, have
suggested that calcium transport can occur in the absence of
protein synthesis (and specifically calcium binding protein
synthesis) when protein synthesis inhibitors are given 185, 86].
Others have shown that while total protein synthesis is severely
diminished following the administration of protein synthesis
inhibitors, the synthesis of calcium binding protein is not
completely abolished [87]. Most investigators currently agree
that protein transport is central to the movement of calcium
across the cell and is dependent upon receptor mediated mech-
anisms. Thus, events that occur in the nucleus of the cell are
vital in facilitating transcellular calcium movement. Events at
other sites may also play a role, though to what extent remains
controversial. Following the administration of 1 ,25-dihydroxy-
vitamin D in vivo, the transport of calcium in the intestine is
biphasic, involving cells located at the tip of villus and those
located at the crypt [88]. Halloran and DeLuca have demon-
strated that after the administration of 1 ,25-dihydroxyvitamin
D3 to the rat, there is an initial increase in calcium transport that
reaches a maximum at about six hours, followed by a decline
and a nadir at about 18 hours. Following this is another increase
Fecal
excretion
at 6 day—
7 day Urinary excretion
Intestinal coil
Fig. 2. Thermodynamic considerations in the movement of calcium
across the intestinal cell. (Taken from Wasserman et al, reference 80,
with permission of the publisher).
in calcium transport that reaches a maximum at 24 to 48 hours.
When a second injection of 1,25-dihydroxyvitamin D3 is given
at 48 hours, only the first rapid component of an increase in
calcium transport is noted. The suggestion is that there are two
populations of cells responding differently—one at the tip of the
villus that responds quickly and another population at the crypt
that migrates up the villus (in 24 to 48 hours) and then plays a
part in calcium transport. The latter population is then still able
to respond to the initial phase of 1,25-dihydroxyvitamin D3
stimulated calcium transport.
The effect of 1,25-dihydroxyvitamin D3 on intracellular and
nuclear events in the intestinal cell
Vitamin D3 via its active metabolite induces the synthesis of
calcium binding and other proteins in different animal species.
Wasserman first reported the induction of chick intestinal
calcium binding protein following the administration of vitamin
D to vitamin D-deficient chicks [89, 90]. This protein has a
molecular weight of approximately 28,000 in chick intestine; its
synthesis is closely related to the vitamin D induced uptake of
calcium by the intestinal cell. The precise manner in which it
helps in the movement of calcium across the intestinal cell is
uncertain; however, it does not act as a "buffer" for calcium
[80, 91]. It is vitamin D-dependent in the intestine and an
increased flux of Ca + across intestinal cells by diffusional
processes in the absence of vitamin D, such as occurs with an
I ,25(OH)2D3
24,25(OH)2D3
MCR
liter/day
44.6 5.7
9.2 + 1.5
PR p.g/day
Biliary
excretion'
6 hr—8 hr
1.5
26.4 7.2
15.6 1%
15.3 1.3
54 6%
48.8 + 2.7
93±3 72±6 54±6
9.2 0.1 9.6 0.1 9.4 0.1
50 my
3.4 0.1
0.7 0.1
2! 3
25 2
45 4
3.6 0.1
0.5 ÷ 0.2
27 2
25 2
41 + 2
0 my —
it Profile
Variable
jCa2]
Profile
Energy (LG)
profile,
assuming luminal
[Ca2] = 10M
C
a)
E
=
-J
3.7 0.1
—0.7 0.1
29 2
31 3
40 -I- 4
14 2% (6 day)
7.4 1.8% (2 day)
— +8
—103M
0
0.
C
E
-J
+7.3
KCa/moi
Basal
Incremental"
37±7 34±5 20±6
64±13 40÷11 253
3.1 + 0.7 3.4 0.3 3.7 0.3
2.9 ÷ 0.4 3.5 ÷ 0.4 4.4 0.6
10°M
0.4
KCaI/mol
( —e.g
J
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increase in dietary calcium does not increase the synthesis of
the protein [80, 91]. Calcium binding proteins are also present in
mammalian intestinal cells. In man, intestinal calcium binding
protein has a molecular weight of approximately 28,000 [92, 93];
in the rat, the protein has a molecular weight of approximately
10,000 [94]; and in the cow, the molecular weight is approxi-
mately 8,500 daltons [95]. The amino acid sequence of bovine
and porcine calcium binding protein have been determined, and
the presumed sequence of rat intestinal calcium binding protein
has been deduced from the sequence of a cDNA clone [96—98].
In addition to the increase in synthesis of calcium binding
protein in vivo and in vitro, Bishop et at have shown that
1 ,25-dihydroxyvitamin D3 increases the synthesis of another
protein (protein 6) of p1 —5.1 and molecular weight >18,000
within 30 minutes of the addition of 1,25-dihydroxyvitamin D3
to chicken embryonic duodena [991. Thirty minutes after the
addition of 1 ,25-dihydroxyvitamin D3 to duodena, the radioac-
tive leucine incorporated in the protein is about one and a half
times that seen in control duodena; approximately three times
more radioactive leucine is incorporated into experimental
duodena at one hour, and about 1.5 times more at 20 hours. The
incorporation of radioactivity into another protein (protein 4), is
inhibited by about 40% within 30 minutes of the addition of
1,25-dihydroxyvitamin D3. The inhibition is sustained for at
least 20 hours. Whether the decrease in incorporation of radio-
active leucine into protein 4 is due to an acceleration in
degradation or due to a decrease in actual synthesis or both is
not certain.
Recently, Shinki et al showed that 1 ,25-dihydroxyvitamin D3
increased ornithine decarboxylase activity in chick intestinal
cells following the administration of 1 ,25-dihydroxyvitamin D3
to vitamin D-deficient chicks [100]. This response occurred
within two hours of the administration of 1 ,25-dihydroxy-
vitamin D3 [100]. The change in ornithine decarboxylase activ-
ity is temporally related to the increase in calcium transport.
The induction of ornithine decarboxylase activity occurred
within crypt and villus cells, but the rate of increase of
putrescine synthesis was much higher in the villus cells [101].
Spermidine Nl-acetyltransferase activity also increases follow-
ing the administration of 1 ,25-dihydroxyvitamin D3 [102]. Initial
reports by Shinki et al reported no increase in 1 ,25-dihydroxy-
vitamin D3 induced activity of S-adenosylmethionine decarbox-
ylase activity [100]. Recently, however, Steeves and Lawson
noted an increase in the activity of this enzyme in chick
intestine after the administration of 1 ,25-dihydroxyvitamin D3
[103]. Mezzetti, Moruzzi and Barbiroli reported an increase in
spermine binding protein following the administration of 1,25-
dihydroxyvitamin D3 [104]. It is likely that polyamine synthesis
is involved in the response of the intestinal cell to 1,25-
dihydroxyvitamin D3. The exact relationship of the observed
responses to calcium transport are not certain, as Steeves has
shown that inhibitors of ornithine decarboxylase such as DL-
a-difiuoromethylornithine HCI (DFMO) and S-adenosylmethi-
onine decarboxylase such as methyiglyoxal bis(guanylhydra-
zone) (MGBG) inhibit the respective enzymes but do not alter
1 ,25-dihydroxyvitamin D3—induced calcium transport [103]. It is
possible, however, that the decarboxylase inhibitors did not
completely deplete the intestinal cells of polyamines. The
relationship between polyamines and I ,25-dihydroxyvitamin D3
requires further study.
The effects of 1,25-dihydroxyvitamin D3 on the induction of
calcium binding protein and other proteins are mediated by a
receptor—dependent mechanism. Brumbaugh and Haussler
have demonstrated the presence of high molecular weight
(—'-64,000), high affinity, low capacity receptors specific for
1 ,25-dihydroxyvitamin D3 in intestinal tissues [105, 106].
Brumbaugh and Haussler have reported on a tempera-
ture—dependent translocation of receptors from cytoplasm into
the nucleus [106]. Free receptors occur in the cytoplasm
whereas occupied receptors are predominantly nuclear in local-
ization [107, 108]. Following the administration of 1,25-
dihydroxyvitamin D3, there is an increase in the chromatin
template activity, as well as an induction of the activity of RNA
polymerase II that results in the synthesis of messenger RNA
[109, 110]. Messenger RNA levels for calcium binding protein
increase following the administration of 1 ,25-dihydroxyvitamin
D3 [111]. Recently, Pike and co-workers have purified the
intestinal 1 ,25-dihydroxyvitamin D3 receptor and have raised
monoclonal antibodies to it [112, 113]. Similar work has been
performed by Simpson and DeLuca using different purification
methods [114]. A radioimmunoassay for the receptor has been
developed and has been used to quantify receptors in fibroblasts
of humans with 1 ,25-dihydroxyvitamin D resistance [115, 116].
Trypsin cleavage of the receptor produces fragments that bind
hormone but not DNA or a specific monoclonal antibody,
showing that there are distinct domains for binding to hormone
or other ligands [117]. The receptor also contains reactive
sulfhydryl groups in its DNA binding dormain [118]. Receptors
are necessary for 1 ,25-dihydroxyvitamin D action. The strong-
est evidence supporting the contention that receptors are nec-
essary for 1 ,25-dihydroxyvitamin D action comes from reports
of 1 ,25-dihydroxyvitamin D3 resistance in patients with vitamin
D-dependency rickets type II. In these patients, clinical rickets
is accompanied by excessively high levels of 1 ,25-dihydroxyvi-
tamin D3 in the plasma and a resistance to the action of the
hormone [119]. There is decreased localization of 1,25-
dihydroxyvitamin D3 in the nuclei of fibroblasts obtained from
these patients, and a direct assay of receptors in the fibroblasts
of such patients has revealed that there is both a decreased
number and an altered affinity of receptors for the hormone
[116]. 1 ,25-Dihydroxyvitamin D3 does not induce the activity of
25-hydroxyvitamin D3-24-hydroxylase as it does in tissue from
normal subjects [119]. Wecksler, Okamura and Norman have
defined the requirements for optimal receptor binding to vita-
min D molecules [120]. The C-l and C-25 hydroxyl groups are
most important for receptor binding followed by the C3
hydroxyl. Similar results were obtained by Eisman and DeLuca
[121]. Shortening of the side chain also reduces binding sub-
stantially [120].
In addition to the effects noted on calcium binding protein,
there are significant effects of 1,25-dihydroxyvitamin D3 on the
uptake of calcium by endoplasmic reticulum and Golgi appara-
tus [122, 123]. 1 ,25-Dihydroxyvitamin D3 also induces cyclic
AMP and cyclic GMP production in embryonal duodena [124,
125]. In summary, there is both induction and suppression of
several proteins in the cytoplasm of the intestinal cell. The
effects appear to be mediated by intracellular receptors for the
hormone.
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Effects of 1,25-dihydroxyvitamin D3 on the luminal cell
membrane
Vitamin D3 or 1 ,25-dihydroxyvitamin D3 alter the biochemi-
cal and morphological characteristics of the intestinal cell
membranes. Following the administration of vitamin D3 to
vitamin D-deficient animals, there is an increase in the size of
the villus as well as an increase in the size of microvilli; an
alteration in the numbers of intracellular organdIes also occurs
[126—130]. We have observed rapid changes in the morphology
of intestinal cells following the administration of 1 ,25-dihydroxy-
vitamin D3 [1311. The villi become larger and more regular
following the administration of 1 ,25-dihydroxyvitamin D3. The
microvilli also become more uniform in appearance. Brush
border membrane vesicles from vitamin D-deficient animals
have depressed calcium uptake when compared with those from
vitamin D-replete animals [86, 132]. This process is not depen-
dent upon the synthesis of new protein [86]. There is an
increase in the synthesis of phosphatidyl choline (by an increase
in the activity of CDP-choline: Sn- 1 ,2-diacylglycerolcholine
phosphotransferase), that increases the ratio of phosphatidyl
choline to phosphatidyl ethanolamine [133]. The increase in
phosphatidylcholine synthesis occurs at the same time as the
increase in calcium transport. Transmethylation pathways in-
volved in the synthesis of phosphatidylcholine from
phosphatidyl ethanolamine are not altered. The acylation of
lysophosphatidyl choline is also enhanced by 1 ,25-dihydroxy-
vitamin D3 as is the deacylation of phosphatidyl choline [134].
At early times after the administration of 1,25-dihydroxyvi-
tamin D3 to vitamin D-deficient chicks, the phosphatidyl
choline to phosphatidyl ethanolamine ratio is not changed [135].
Rasmussen and co-workers have suggested that alteration in the
ratio of phosphatidyl choline to phosphatidyl ethanolamine
alters the fluidity of the membrane, and thereby allows calcium
to diffuse into the cell [136]. Direct measurements of membrane
fluidity in intestinal cells, however, have not confirmed this
hypothesis [137].
Wasserman and his colleagues have noted alterations in the
rate of 32P incorporation into high molecular weight proteins
upon the administration of vitamin D3 to vitamin D-deficient
animals [80, 138]. Incorporation of radiolabeled phosphorus
into high molecular weight proteins has also been found by
Lawson and Wilson, and de Jong, Ghijsen and Van Os follow-
ing the administration of vitamin D analogs to vitamin D-
deficient animals [139, 140]. Kowarsky and Schachter have
noted the induction of a protein that they have termed "intes-
tinal membrane calcium binding protein" upon the administra-
tion of vitamin D to vitamin D-deficient animals [141]. There
have been other reports of the synthesis of other membrane
proteins following the administration of vitamin D3 analogs to
vitamin D-deficient animals [142, 143]. These proteins appear to
be induced in a temporal sequence that parallels the increase in
calcium transport following the administration of vitamin D,
and it is possible that they may play a role in the translocation
of calcium across the brush border membrane. The specific
activity of cell surface enzymes such as maltase and sucrase is
diminished [144]. The sensitivity of cell membranes to proteo-
lytic enzymes is also altered following the administration of
vitamin D3 to vitamin D-deficient animals [145]. Wilson and
Lawson have reported the increased synthesis of a membrane
protein that resembles actin and have suggested that this may
be important in the translocation of calcium across brush border
membranes [146]. Alkaline phosphatase and calcium—depend-
ent ATPase activities are also enhanced in luminal cell mem-
branes [147—149]. Thus, vitamin D analogs noticeably alter the
structure and composition of cell surface proteins and lipids in
a time frame that is similar to that of the increase in calcium
transport brought about by the sterols. The precise association
of any single event with calcium transport is not clear. Cer-
tainly, a calcium specific, transmembrane translocating protein
has not been identified.
Events at the contraluminal border of the intestinal cell
Based on some of the thermodynamic considerations given
above, it is likely that 1,25-dihydroxyvitamin D3 is involved in
increasing the active extrusion of calcium from the intestinal
cell at the basolateral membrane. Recently, Ghijsen and Van Os
have noted that there is an increase in the activity of a
calcium—dependent ATPase isolated from basolateral mem-
brane following the administration of 1 ,25-dihydroxyvitamin D3
[150], Meyer and Wasserman have also observed vitamin D3
induced ATP-dependent increases in calcium transport in baso-
lateral membranes [1511. This event may be important in the
movement of calcium out of the cell and into the extracellular
fluid.
Multiple effects of 1 ,25-dihydroxyvitamin D3 on the
enterocyte
There is considerable evidence now that 1 ,25-dihydroxyvi-
tamin D3 has multiple effects both at the luminal membrane,
within the cell and at the basolateral membrane. Shultz, Boll-
man and Kumar have performed experiments to show that the
uptake of calcium by brush border membrane vesicles alone is
not sufficient to cause the movement of calcium through the
intestinal epithelial cell layer [1521. The control point resides
within the cell, such as at the level of protein synthesis or at the
contraluminal membrane. Wasserman et al have suggested that
the luminal events (uptake of calcium into the cell) are more
rapid in the onset than the cellular events (such as calcium
binding protein synthesis) [135]. The former (luminal) events
are associated with the synthesis of phospholipids and are not
protein—dependent, whereas the intracellular events are
protein—dependent [135].
In conclusion, 1,25-dihydroxyvitamin D has diverse effects
on the enterocyte. While luminal membrane calcium uptake
may not be protein—dependent, the movement of this divalent
cation across the cell is dependent on the synthesis of proteins
induced by receptor mediated mechanisms in a manner analo-
gous with that of other steroids such as estrogens. Contralu-
minal enzymes such as calcium ATPase are most probably
involved in the extrusion of calcium out of the cell into the
extracellular fluid.
Effects of vitamin D and its metabolites on the kidney
The nature of the 25-hydroxyvitamin D3 la-hydroxylase, its
localization and regulatory factors have been covered in a
previous section. The effect of vitamin D3 and its various
metabolites on ion transport are much less marked on the
kidney than on the intestine and conflicting data have been
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reported. Vitamin D3 increases the tubular reabsorption of
phosphate and calcium in the intact rat and dog [153, 154].
Similarly, 25-hydroxyvitamin D3 increases the reabsorption of
sodium, calcium, phosphate, and bicarbonate in the intact rat
and dog [154—157]. In the thyroparathyroidectomized dog and
rat, the antiphosphaturic effect of 25-hydroxyvitamin D3 is
absent; infusion of parathyroid hormone restores the antiphos-
phaturic effect [154-157]. The effect of 25-hydroxyvitamin D3
on phosphate reabsorption can occur in the thyroparathyroid-
ectomized rat in the presence of vasopressin [158]. The effect of
25-hydroxyvitamin D3 on calcium reabsorption may be a distal
tubular effect [159].
1 ,25-Dihydroxyvitamin D3 also increases the reabsorption of
phosphate in the intact dog and hamster [158, 160, 161]. The
effect is noted only in the presence of parathyroid hormone
[158, 160, 161]. Vasopressin is also able to mimic the action of
parathyroid hormone in this respect [158]. In the parathyroid-
ectomized rat, 1 ,25-dihydroxyvitamin D3 has either no effect or
a phosphaturic effect [158, 160—1631. The effect of 1,25-
dihydroxyvitamin D3 on calcium transport is not clearly estab-
lished. Some have found a decrease in the amount of urinary
calcium excreted following the administration of 1,25-
dihydroxyvitamin D3; others have not been able to find a
decrease (in fact an increase, in some instances) in urinary
calcium excretion following the administration of 1,25-
dihydroxyvitamin D3 [160, 161, 164, 165]. Kurnik and Hruska
have suggested that the effect of 1 ,25-dihydroxyvitamin D3 on
phosphate transport is mediated by changes in lipid composi-
tion of membrane [166].
The localization of the 25-hydroxyvitamin D3- 1 a-hydroxylase
enzyme has been alluded to above [34, 351. The enzyme is a
mitochondrial enzyme located exclusively in the proximal tu-
bules [36—38]. Receptors for 1 ,25-dihydroxyvitamin D3 are
located in the distal tubule of the kidney [167]. One report
suggests that there are receptors in the proximal tubule also
[168]. Examination of the vitamin-D—dependent calcium bind-
ing protein in the tubule reveals that it is located in the distal
tubule [168—170]. Based on available information, it is clear that
I ,25-dihydroxyvitamin D3 exerts a significant effect on the
distal tubule by inducing the synthesis of calcium binding
protein. As receptors for the hormone are also present in this
segment of the tubule, it is very likely that receptors are
involved in the induction of the calcium binding protein.
Summary
Much has been learned about the formation of the active
metabolite of vitamin D3, 1 ,25-dihydroxyvitamin D3. Informa-
tion concerning its formation and catabolism has allowed a clear
understanding of factors involved in the maintenance of plasma
concentrations of the hormone. The effects of I ,25-dihydroxy-
vitamin D3 on calcium transporting cells in the intestine are
marked and well defined. The tissue (intestinal tissue) is easily
isolated and manipulated and hence, this is an ideal tissue in
which to examine the mechanism of divalent cation transport.
The mechanism by which 1,25-dihydroxyvitamin D3 brings
about this effect should help in understanding sterol hormone
action.
RMIv KUMAR
Mayo Clinic
Rochester, Minnesota, USA
Note added in proof
There is a high degree of homology between NH2-termini of rat and
human vitamin D binding protein [25, 172, 1731.
Reprint requests to Rajiv Kumar, M.D., Professor of Medicine,
Mayo Clinic, Endocrine Research Unit, Rochester, Minnesota 55905,
USA.
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